Cellectar Biosciences, Inc. Share-based Payment Arrangement, Accelerated Cost
Cellectar Biosciences, Inc. (CLRB) reported Share-based Payment Arrangement, Accelerated Cost of $47.85 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-05-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2015-05-20
- Cellectar Biosciences, Inc. share-based payment arrangement, accelerated cost for the quarter ending 2011-03-31 was $58.00K.
- Cellectar Biosciences, Inc. share-based payment arrangement, accelerated cost for fiscal 2014 was $47.85K, a 91.60% decline from fiscal 2013.
- Cellectar Biosciences, Inc. share-based payment arrangement, accelerated cost for fiscal 2013 was $569.50K.
| Period end | Share-based Payment Arrangement, Accelerated Cost 1 month | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 12 month |
|---|---|---|---|
| 2014-12-31 | $47.85K 10-K · filed 2015-05-20 | ||
| 2013-12-31 | $569.50K 10-K · filed 2015-05-20 | ||
| 2013-11-30 | $101.97K 10-K · filed 2015-05-20 | ||
| 2011-03-31 | $58.00K 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |